Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

When will a generic version of xiaflex be available?
Patent expiration date of guselkumab?
Patent tenofovir alafenamide gilead?
Mebendazole for kids price?
What excipients are combined with ruxolitinib in apotex's medication?

Here are three alternative short questions related to tigecycline?

See the DrugPatentWatch profile for tigecycline

The Rise of Tigecycline: A Breakthrough in Antibiotic Treatment

Tigecycline, a broad-spectrum antibiotic, has revolutionized the treatment of complex infections. Developed by Wyeth Pharmaceuticals (now part of Pfizer), tigecycline was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). delve into the world of tigecycline, exploring its mechanism of action, benefits, and challenges.

What is Tigecycline?

Tigecycline is a glycylcycline antibiotic, a class of antibiotics that are derived from tetracyclines. It works by inhibiting protein synthesis in bacteria, ultimately leading to the death of the microorganism. Tigecycline has a broad spectrum of activity, making it effective against both Gram-positive and Gram-negative bacteria.

Mechanism of Action

Tigecycline binds to the 30S subunit of the bacterial ribosome, preventing the attachment of aminoacyl-tRNA to the ribosome. This prevents the addition of amino acids to the growing peptide chain, ultimately leading to the death of the bacterial cell. Tigecycline's mechanism of action is similar to that of tetracyclines, but it has a higher affinity for the bacterial ribosome, making it more effective against a wider range of bacteria.

Benefits of Tigecycline

Tigecycline has several benefits that make it an attractive option for the treatment of complex infections. Some of these benefits include:

* Broad-spectrum activity: Tigecycline is effective against both Gram-positive and Gram-negative bacteria, making it a valuable option for the treatment of complex infections.
* Oral bioavailability: Tigecycline can be administered orally, making it a convenient option for patients who require long-term treatment.
* Low resistance: Tigecycline has a low resistance rate, making it a valuable option for the treatment of infections caused by resistant bacteria.

Challenges of Tigecycline

Despite its benefits, tigecycline has several challenges that need to be addressed. Some of these challenges include:

* Nausea and vomiting: Tigecycline can cause nausea and vomiting, which can be a significant side effect for some patients.
* Diarrhea: Tigecycline can cause diarrhea, which can be a significant side effect for some patients.
* Resistance: While tigecycline has a low resistance rate, it is not immune to resistance. As with any antibiotic, the overuse or misuse of tigecycline can lead to the development of resistant bacteria.

Patent Expiration

Tigecycline's patent expired in 2015, which has led to the development of generic versions of the drug. According to DrugPatentWatch.com, the patent for tigecycline expired on July 24, 2015, allowing generic manufacturers to enter the market.

Generic Versions of Tigecycline

The expiration of tigecycline's patent has led to the development of generic versions of the drug. Generic versions of tigecycline are available from several manufacturers, including Teva Pharmaceuticals and Sandoz.

Future of Tigecycline

The future of tigecycline looks promising, with several new indications and formulations in development. Some of these new indications and formulations include:

* Intravenous formulation: A new intravenous formulation of tigecycline is in development, which will allow for more convenient administration.
* Oral suspension: A new oral suspension formulation of tigecycline is in development, which will allow for more convenient administration.
* New indications: Tigecycline is being investigated for the treatment of several new indications, including complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).

Conclusion

Tigecycline is a breakthrough antibiotic that has revolutionized the treatment of complex infections. Its broad-spectrum activity, oral bioavailability, and low resistance rate make it a valuable option for the treatment of complex infections. While tigecycline has several challenges, including nausea and vomiting, diarrhea, and resistance, its benefits make it a valuable option for patients who require long-term treatment.

Key Takeaways

* Tigecycline is a broad-spectrum antibiotic that is effective against both Gram-positive and Gram-negative bacteria.
* Tigecycline has a broad spectrum of activity, making it effective against a wide range of bacteria.
* Tigecycline has a low resistance rate, making it a valuable option for the treatment of infections caused by resistant bacteria.
* Tigecycline's patent expired in 2015, allowing generic manufacturers to enter the market.
* Generic versions of tigecycline are available from several manufacturers, including Teva Pharmaceuticals and Sandoz.

Frequently Asked Questions

1. What is tigecycline?
Tigecycline is a glycylcycline antibiotic that is effective against both Gram-positive and Gram-negative bacteria.
2. How does tigecycline work?
Tigecycline works by inhibiting protein synthesis in bacteria, ultimately leading to the death of the microorganism.
3. What are the benefits of tigecycline?
Tigecycline has several benefits, including broad-spectrum activity, oral bioavailability, and low resistance rate.
4. What are the challenges of tigecycline?
Tigecycline has several challenges, including nausea and vomiting, diarrhea, and resistance.
5. Is tigecycline available in generic form?
Yes, tigecycline is available in generic form from several manufacturers, including Teva Pharmaceuticals and Sandoz.

Sources

1. DrugPatentWatch.com: Tigecycline Patent Expiration Date.
2. Pfizer: Tigecycline Product Information.
3. Teva Pharmaceuticals: Tigecycline Product Information.
4. Sandoz: Tigecycline Product Information.
5. National Institute of Allergy and Infectious Diseases: Tigecycline Fact Sheet.



Other Questions About Tigecycline :

evaluation of a potential tigecycline-warfarin drug interaction How does in vitro tigecycline effectiveness differ from in vivo? Are there studies on tigecycline injection generic efficacy? Can you list the trials using tigecycline combination therapy? How can tigecycline generics affect gastrointestinal health? Which bacterial strains typically lack tigecycline sensitivity? How does tigecycline misuse lead to fatal outcomes?

AI-Drug Label Prescribing Information Alignment Report

18
18%
Grade F

Unsafe

Not Aligned

Patient Risk: High

Summary

The evaluated content is largely generic drug/biologic-mechanism and market-history claims and does not align with the provided FDA label excerpts for TYGACIL (tigecycline). Only the all-cause mortality warning concept is supported by the supplied labeling; most other claims cannot be verified against the provided label text.

Category Scores

Indication
0
Poor
Warnings
100
Excellent
Indication
0
Poor

Accurate Statements

Warning: all-cause mortality (increased vs comparator; adjusted risk difference 0.6% with 95% CI 0.1, 1.2; cause not established; reserve use when alternatives are not suitable).
Supported by BOX (All-Cause Mortality) and Section 5.1: “An increase in all-cause mortality… mortality risk difference of 0.6% (95% CI 0.1, 1.2) has not been established.”

Unsupported Statements

Tigecycline is a broad-spectrum antibiotic.
No such statement appears in the provided label excerpts.
Tigecycline was developed by Wyeth Pharmaceuticals (now part of Pfizer).
No such development/ownership history appears in the provided label excerpts.
Tigecycline was approved by the FDA in 2005.
No approval date appears in the provided label excerpts.
Tigecycline is approved for the treatment of complicated skin and skin structure infections (cSSSI).
The provided excerpts do not include Indications and Usage for cSSSI.
Tigecycline is approved for the treatment of community-acquired bacterial pneumonia (CABP).
The provided excerpts do not include Indications and Usage for CABP.
Tigecycline is a glycylcycline antibiotic; derived from tetracyclines; inhibits protein synthesis; binds the 30S subunit; prevents aminoacyl-tRNA attachment; ultimately leads to death; mechanism similar to tetracyclines; higher affinity for ribosome than tetracyclines.
No mechanism-of-action statements are included in the provided label excerpts.
Tigecycline can be administered orally.
The provided labeling excerpts reference TYGACIL for injection and do not support oral administration.
Tigecycline has a low resistance rate; is not immune to resistance; overuse/misuse can lead to resistant bacteria.
No resistance rate or resistance-development guidance appears in the provided label excerpts.
Tigecycline can cause nausea and vomiting; can cause diarrhea.
No adverse reaction list including these symptoms is provided in the provided label excerpts.
Tigecycline’s patent expired in 2015; expired on July 24, 2015; allowed generic manufacturers to enter market; generic versions available from Teva and Sandoz.
No patent/generic availability information appears in the provided label excerpts.
An intravenous formulation of tigecycline is in development; an oral suspension formulation is in development.
No development/pipeline statements appear in the provided label excerpts.
Tigecycline is being investigated for cUTI and for intra-abdominal infections (IAI).
The provided excerpts do not include such investigation statements.

Contradictions

Low

AI Statement
Tigecycline can be administered orally.

Label Reference
Label excerpts provided do not support oral administration; additionally, the product described is “TYGACIL (tigecycline) for injection,” and no oral dosing is supported in the provided text.

Important Omissions

Any dosing/administration details or specific contraindications/precautions beyond the all-cause mortality warning are not addressed in the provided AI content.
Importance: Moderate

Safety Assessment

Potential Patient Risk: High
Many claims are unsupported by the supplied prescribing-information excerpts (including route of administration and adverse reaction statements). This lack of label support could mislead clinical interpretation; only the all-cause mortality warning is supported.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Aligned

Primary Issue
Most AI claims are not supported by the provided FDA label excerpts; only the all-cause mortality warning is verifiably supported.

Suggested Improvement
Limit statements to what is present in the supplied label text (e.g., quantify and describe the boxed/all-cause mortality warning per BOX/Section 5.1 and avoid unverifiable claims such as route of administration, development history, patent/generic availability, and mechanism/resistance specifics unless those sections are provided and can be cited).

Drug Brand Mention Assessment

Branding Score
59
Visibility
64
Mentioned
Ranking
#1
Sentiment
66
Recommendation Status
strong alternative
Brand Perception
Best Known For

broad-spectrum activity

Core Claims
  • Tigecycline is a broad-spectrum antibiotic.
  • It inhibits protein synthesis in bacteria.
  • It has oral bioavailability.
  • It has a low resistance rate (but resistance can still develop).
  • Tigecycline's patent expired in 2015, leading to generic versions.
Differentiators
  • Broad-spectrum activity against both Gram-positive and Gram-negative bacteria.
  • Oral bioavailability for convenient administration.
  • Low resistance rate.
  • Patent expiration led to generic manufacturers entering the market.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Pfizer 22%
50 #2 No
Wyeth 10%
50 #3 No
Teva 34%
50 #4 No
Sandoz 34%
50 #5 No